ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "BioTime, Inc." (BTX) Report Updated: Aug 22, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"BioTime, Inc." (BTX)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: MNOV,SPHS,CYTK,EXEL

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"BioTime, Inc."© quotemedia

Company Profile

BioTime, Inc., a biotechnology company, engages in the research and product development in the field of regenerative medicine. The company focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including PureStem human embryonic progenitor cell lines; associated ESpan culture media; human embryonic stem cell lines; HyStem hydrogel products; and Hextend, a blood plasma volume expander for hypovolemia in surgery, emergency trauma, and other applications. The company’s clinical programs include OpRegen and OpRegen-Plus, which are in Phase I/IIa trial for the treatment of the dry form of age-related macular degeneration; AST-OPC1 that is in Phase I/IIa trial for spinal cord injuries; Renevia, which is in pivotal trial for HIV-related lipoatrophy; and AST-VAC2 that is in pre-clinical stage for non-small cell lung cancer. It is also developing Premvia, a hydrogel formulation of cross-linked thiol-modified hyaluronan and thiol-modified gelatin to manage wounds; ReGlyde, a cross-linked thiol-modified hyaluronan hydrogel to manage and protect tendon injuries; and PanC-Dx, a diagnostic product used to detect breast, bladder, and lung cancers, as well as mobile health software products. In addition, the company markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; VarElect, an application for prioritizing gene variants; and MalaCards, a database of human diseases, as well as analysis tools. Further, it develops cell based therapeutic products for diseases, such as neurological, cancer, age related macular degeneration, orthopedic, and age-related cardiovascular diseases. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.